Suzhou Alphamab Co., Ltd.
Clinical trials sponsored by Suzhou Alphamab Co., Ltd., explained in plain language.
-
New shot could cut bleeding episodes in hemophilia patients
Disease control OngoingThis study tests a new medicine called KN057 to see if it can prevent bleeding episodes in people with hemophilia A or B who do not have inhibitors. About 125 participants will receive either KN057 or standard care for up to 52 weeks. The goal is to measure how well KN057 reduces…
Phase: PHASE3 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New shot aims to stop bleeds in Tough-to-Treat hemophilia
Disease control OngoingThis study tests a medicine called KN057 to see if it can prevent bleeding episodes in people with hemophilia A or B who have developed inhibitors (antibodies that block standard treatment). About 53 participants will be randomly assigned to receive either KN057 injections regula…
Phase: PHASE3 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New blood thinner aims to prevent dangerous clots after knee surgery
Prevention OngoingThis study tests a new drug called KN060 to see if it can prevent blood clots in people having knee replacement surgery. About 241 adults took part and received either KN060 or a standard blood thinner. The goal is to find a safer and more effective way to avoid serious clots aft…
Phase: PHASE2 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Prevention
Last updated May 26, 2026 05:30 UTC